Skip Navigation

European Heart Journal 2003 24(19):1705-1706; doi:10.1016/S0195-668X(03)00392-0
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ørn, S.
Right arrow Articles by Dickstein, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ørn, S.
Right arrow Articles by Dickstein, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Neurohormonal inhibition in heart failure, is there no limit?

Stein Ørna,* and Kenneth Dicksteinb

a Cardiology Division, Central Hospital in Rogaland, Stavanger, Norway
b University of Bergen, Central Hospital in Rogaland, Stavanger, Norway

* Corresponding author. Tel.: +00-47-51-51-80-00
E-mail address: orst@sir.no

E-mail address: trout@online.no

Received 4 July 2003; accepted 9 July 2003

The first 10% of the full text of this article appears below.

See doi:10.1016/S1095-668X(03)00477-9for the article to which this editorial refers

The strategy supporting effective pharmacological treatment in heart failure patients stems from appreciation of the deleterious effects of chronic neurohormonal activation. Increasingly comprehensive treatment strategies that inhibit neurohormonal activation have evolved in an add-on fashion in the belief that the more complete the neurohormonal inhibition, the better. However, there is a downside to excessive neurohormonal inhibition, since an operational neurohormonal system is necessary to maintain homeostasis also in patients with heart failure. The aim of neurohormonal inhibition should not be to completely dismantle the neurohormonal system, but rather inhibit excessive activation, leaving autoregulatory functions and useful . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure
Robert S. McKelvie, Jean-Lucien Rouleau, Michel White, Rizwan Afzal, James B. Young, Aldo P. Maggioni, Peter Held, and Salim Yusuf
EHJ 2003 24: 1727-1734. [Abstract] [Full Text]